Aliases & Classifications for Spinocerebellar Degeneration

Aliases & Descriptions for Spinocerebellar Degeneration:

Name: Spinocerebellar Degeneration 51 69
Spinocerebellar Tract Degeneration 69
Spinocerebellar Degenerations 52
Ataxia, Spinocerebellar 69

Summaries for Spinocerebellar Degeneration

NINDS : 51 Ataxia often occurs when parts of the nervous system that control movement are damaged. People with ataxia experience a failure of muscle control in their arms and legs, resulting in a lack of balance and coordination or a disturbance of gait. While the term ataxia is primarily used to describe this set of symptoms, it is sometimes also used to refer to a family of disorders. It is not, however, a specific diagnosis.

MalaCards based summary : Spinocerebellar Degeneration, also known as spinocerebellar tract degeneration, is related to spinocerebellar degeneration and corneal dystrophy and ataxias and cerebellar or spinocerebellar degeneration, and has symptoms including ataxia, cerebellar ataxia and myoclonus. An important gene associated with Spinocerebellar Degeneration is ATXN1 (Ataxin 1), and among its related pathways/superpathways is Chks in Checkpoint Regulation. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, cerebellum and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Related Diseases for Spinocerebellar Degeneration

Diseases related to Spinocerebellar Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 spinocerebellar degeneration and corneal dystrophy 11.9
2 ataxias and cerebellar or spinocerebellar degeneration 11.8
3 spinocerebellar degeneration with macular corneal dystrophy, congenital cataracts, and myopia 11.8
4 primary cerebellar degeneration 11.0
5 spinocerebellar ataxia 2 11.0
6 mousa al din al nassar syndrome 10.8
7 hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency 10.8
8 ataxia with isolated vitamin e deficiency 10.8
9 mitochondrial recessive ataxia syndrome 10.8
10 laurence-moon syndrome 10.8
11 behr syndrome 10.8
12 ataxia 10.2
13 neuronitis 10.2
14 adrenoleukodystrophy 10.0
15 cyprus facial neuromusculoskeletal syndrome 10.0 ATXN1 ATXN3
16 osteopathia striata with cranial sclerosis 9.9 ATXN1 ATXN3
17 charcot-marie-tooth disease, axonal, type 2l 9.9 ATXN2 ATXN3
18 neuropathy 9.9
19 motor neuron disease 9.9
20 cerebritis 9.9
21 hemochromatosis, type 2a 9.9 ATXN2 ATXN3
22 spinocerebellar ataxia, autosomal recessive 3 9.9 ATXN1 ATXN3
23 holoprosencephaly 9.8 ATXN1 ATXN2 ATXN3
24 epileptic encephalopathy, early infantile, 21 9.8 ATXN1 ATXN2 ATXN3
25 osteoporosis 9.8 ATXN1 ATXN2 ATXN3
26 multiple system atrophy 9.8
27 histiocytosis 9.8
28 proteus syndrome, somatic 9.8 ATXN1 ATXN2 ATXN3
29 dipetalonemiasis 9.8 ATXN1 ATXN2 ATXN3
30 hermansky-pudlak syndrome 3 9.8 ATXN1 ATXN2 ATXN3
31 acute interstitial pneumonia 9.8 ATXN2 ATXN3
32 cephalic disorders 9.8 ATXN1 ATXN2 ATXN3
33 hepatitis 9.7
34 celiac disease 9.7
35 hereditary ataxia 9.7
36 hereditary spastic paraplegia 9.7
37 hypoglycemia 9.7
38 brainstem auditory evoked responses 9.7
39 friedreich ataxia 9.7
40 hereditary sensory neuropathy 9.7
41 blind loop syndrome 9.7
42 wilson disease 9.7
43 tooth disease 9.7
44 amenorrhea 9.7
45 encephalopathy 9.7
46 facial hemiatrophy 9.7
47 myoclonus 9.7
48 corneal dystrophy 9.7
49 paraneoplastic syndromes 9.7
50 roussy-levy syndrome 9.7

Comorbidity relations with Spinocerebellar Degeneration via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Degeneration

Graphical network of the top 20 diseases related to Spinocerebellar Degeneration:



Diseases related to Spinocerebellar Degeneration

Symptoms & Phenotypes for Spinocerebellar Degeneration

UMLS symptoms related to Spinocerebellar Degeneration:


ataxia, cerebellar ataxia, myoclonus

GenomeRNAi Phenotypes related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.5 ATXN3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.5 ATXN3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.5 ATXN3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.5 ATXN3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.5 GLUD1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.5 ATXN3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.5 GLUD1 ATXN3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.5 ATXN3 GLUD1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.5 GLUD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.5 GLUD1 ATXN3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.5 GLUD1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.5 ATXN3

MGI Mouse Phenotypes related to Spinocerebellar Degeneration:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.02 ATXN1 ATXN2 ATXN3 GLUD1 TDP1

Drugs & Therapeutics for Spinocerebellar Degeneration

Drugs for Spinocerebellar Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
5
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Amantadine Approved Phase 4 768-94-5 2130
8
Metformin Approved Phase 4 657-24-9 14219 4091
9 insulin Phase 4
10 Estradiol valerate Phase 4 979-32-8
11 Analgesics Phase 4,Phase 1,Phase 2
12 Mitogens Phase 4
13 Adrenergic Agents Phase 4
14 Adrenergic Agonists Phase 4
15 Adrenergic alpha-2 Receptor Agonists Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
18 Contraceptive Agents Phase 4
19 Sympatholytics Phase 4
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
24 Estradiol 17 beta-cypionate Phase 4
25 Estradiol 3-benzoate Phase 4
26 Estrogens Phase 4
27 Polyestradiol phosphate Phase 4
28 Insulin, Globin Zinc Phase 4
29 Antihypertensive Agents Phase 4,Phase 2
30 Autonomic Agents Phase 4,Phase 3,Early Phase 1
31
Serotonin Phase 4 50-67-9 5202
32 Muscarinic Antagonists Phase 4
33 Cholinergic Agents Phase 4,Phase 2,Phase 3
34 Cholinergic Antagonists Phase 4
35 Serotonin Agents Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Neurotransmitter Uptake Inhibitors Phase 4
38 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
41 Parasympatholytics Phase 4
42 Dopamine Agents Phase 4
43 Dopamine Uptake Inhibitors Phase 4
44 Hypoglycemic Agents Phase 4,Phase 3
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2
46 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Antidepressive Agents, Second-Generation Phase 4
48 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
49 Antiviral Agents Phase 4,Phase 3,Phase 2
50 Antiparkinson Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 113)
id Name Status NCT ID Phase
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4
2 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4
3 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4
4 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Recruiting NCT02733679 Phase 4
5 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3
6 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3
7 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3
8 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3
9 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3
10 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3
11 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3
12 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3
13 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3
14 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3
15 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3
16 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3
17 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3
18 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3
19 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3
20 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3
21 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Recruiting NCT02889302 Phase 3
22 Trial in Adult Subjects With Spinocerebellar Ataxia Recruiting NCT02960893 Phase 2, Phase 3
23 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3
24 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3
25 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Unknown status NCT02039206 Phase 2
26 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
27 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
28 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2
29 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2
30 Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Completed NCT00992771 Phase 2
31 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
32 Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2) Completed NCT00998634 Phase 2
33 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2
34 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2
35 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2
36 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2
37 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2
38 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2
39 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2
40 EPI-743 in Friedreich's Ataxia Point Mutations Completed NCT01962363 Phase 2
41 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Completed NCT01728064 Phase 2
42 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2
43 A Study of Resveratrol as Treatment for Friedreich Ataxia Completed NCT01339884 Phase 1, Phase 2
44 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Completed NCT01035671 Phase 2
45 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2
46 A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00897221 Phase 2
47 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2
48 Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia Completed NCT00631202 Phase 2
49 A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00530127 Phase 1, Phase 2
50 Idebenone to Treat Friedreich's Ataxia Completed NCT00229632 Phase 2

Search NIH Clinical Center for Spinocerebellar Degeneration

Genetic Tests for Spinocerebellar Degeneration

Anatomical Context for Spinocerebellar Degeneration

MalaCards organs/tissues related to Spinocerebellar Degeneration:

39
Eye, Cerebellum, Testes, Skin, Brain, Bone

Publications for Spinocerebellar Degeneration

Articles related to Spinocerebellar Degeneration:

(show top 50) (show all 144)
id Title Authors Year
1
MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. ( 27536377 )
2016
2
A Homozygous RAB3GAP1:c.743delC Mutation in Rottweilers with Neuronal Vacuolation and Spinocerebellar Degeneration. ( 26968732 )
2016
3
Spinocerebellar degeneration: Discrepancies between clinical and pathological diagnoses. ( 26556659 )
2015
4
"Cerebellar peduncle quarter notes" formed by the superior and middle cerebellar peduncles: comparison with a diffusion tensor study of spinocerebellar degeneration. ( 25749832 )
2015
5
Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration. ( 24781836 )
2014
6
Progressive cerebellar atrophy: hereditary ataxias and disorders with spinocerebellar degeneration. ( 23622410 )
2013
7
Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. ( 23128836 )
2013
8
Acoustic characteristics of ataxic speech in Japanese patients with spinocerebellar degeneration (SCD). ( 22268904 )
2012
9
Secondary amenorrhea in a woman with spinocerebellar degeneration treated with thyrotropin-releasing hormone: a case report and in vitro analysis. ( 22152284 )
2011
10
Anesthetic management of a patient with spinocerebellar degeneration. ( 21772692 )
2011
11
Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. ( 20809107 )
2010
12
Tract-by-tract morphometric and diffusivity analyses in vivo of spinocerebellar degeneration. ( 19021844 )
2009
13
Cognitive impairment in spinocerebellar degeneration. ( 19295212 )
2009
14
Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. ( 19286195 )
2009
15
Analysis of subjective evaluations of the functions of tele-coaching intervention in patients with spinocerebellar degeneration. ( 18525137 )
2008
16
Effect of coaching on psychological adjustment in patients with spinocerebellar degeneration: a pilot study. ( 17984151 )
2007
17
Catatonic stupor superimposed on hereditary spinocerebellar degeneration resolved with electroconvulsive therapy. ( 16764981 )
2006
18
Longitudinal study of bone and calcium metabolism and fracture incidence in spinocerebellar degeneration. ( 17035703 )
2006
19
Adrenoleukodystrophy manifesting as spinocerebellar degeneration. ( 16804268 )
2006
20
Thalamic stimulation for disabling tremor in a patient with spinocerebellar degeneration. ( 16155369 )
2005
21
Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. ( 15845214 )
2005
22
Peripheral nerve pathology in two rottweilers with neuronal vacuolation and spinocerebellar degeneration. ( 16301586 )
2005
23
[Clinical features and molecular genetics of autosomal recessive spinocerebellar degenerations]. ( 15651291 )
2004
24
Spinocerebellar degeneration with negative electroretinogram: dysfunction of the bipolar cells. ( 15573948 )
2004
25
Spinocerebellar degeneration. ( 14521474 )
2003
26
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration. ( 12736088 )
2003
27
Nystagmus-sensation dissociation in spinocerebellar degeneration. ( 14606594 )
2003
28
Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. ( 12788952 )
2003
29
Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. ( 11784843 )
2002
30
Ambulatory blood pressure monitoring in patients with spinocerebellar degeneration. ( 12225317 )
2002
31
Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. ( 11897246 )
2002
32
Reduced pre-movement facilitation of motor evoked potentials in spinocerebellar degeneration. ( 11440743 )
2001
33
Clinical and genetic aspects of spinocerebellar degeneration. ( 10970057 )
2000
34
Vestibular evoked myogenic potentials in patients with spinocerebellar degeneration. ( 11132714 )
2000
35
Diffusion- and T2-weighted MRI of the transverse pontine fibres in spinocerebellar degeneration. ( 11151684 )
2000
36
A novel point mutation in X-linked adrenoleukodystrophy presenting as a spinocerebellar degeneration. ( 10319888 )
1999
37
Parvocellular and magnocellular visual processing in spinocerebellar degeneration and Parkinson's disease: an event-related potential study. ( 10402092 )
1999
38
Chronic vitamin E deficiency causing spinocerebellar degeneration, peripheral neuropathy, and centro-cecal scotomata. ( 10198917 )
1999
39
Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. ( 10674722 )
1999
40
Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. ( 10367323 )
1999
41
Molecular genetic diagnosis of Friedreich's ataxia in a pedigree with apparent autosomal dominant spinocerebellar degeneration. ( 9886474 )
1999
42
Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial. ( 10397076 )
1999
43
Late-onset progressive spinocerebellar degeneration in Brittany Spaniel dogs. ( 9678519 )
1998
44
Stress induced urinary incontinence in patients with spinocerebellar degeneration. ( 9527157 )
1998
45
Optic disc edema associated with spinocerebellar degeneration. ( 9672220 )
1998
46
Histopathological and ultrastructural features of feline hereditary cerebellar cortical atrophy: a novel animal model of human spinocerebellar degeneration. ( 9797002 )
1998
47
Power spectral analysis of auditory brainstem responses and MRI findings in patients with spinocerebellar degeneration. ( 9809225 )
1998
48
The laryngeal lesion in young dogs with neuronal vacuolation and spinocerebellar degeneration. ( 9684979 )
1998
49
CNS sequelae in Langerhans cell histiocytosis: progressive spinocerebellar degeneration as a late manifestation of the disease. ( 9383811 )
1997
50
Neuronal vacuolation and spinocerebellar degeneration in young Rottweiler dogs. ( 9240838 )
1997

Variations for Spinocerebellar Degeneration

Expression for Spinocerebellar Degeneration

Search GEO for disease gene expression data for Spinocerebellar Degeneration.

Pathways for Spinocerebellar Degeneration

Pathways related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ATXN1 ATXN2 ATXN3

GO Terms for Spinocerebellar Degeneration

Cellular components related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 8.96 ATXN1 ATXN3
2 nuclear inclusion body GO:0042405 8.62 ATXN1 ATXN3

Molecular functions related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 8.96 ATXN1 ATXN2
2 identical protein binding GO:0042802 8.8 ATXN1 ATXN3 GLUD1

Sources for Spinocerebellar Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....